GSE137514 A genetic variant controls interferon- β gene expression in human myeloid cells by preventing C/EBP-β binding on a conserved enhancer

Contributor : Germain RousseletSeries Type : Expression profiling by high throughput sequencingOrganism : Mus musculusInterferon beta is a central cytokine in the antiviral response and the immunogenicity of cancer therapies. In monocytes, its expression is modulated by a 60 kb downstream eQTL. We found that this eQTL disrupts binding of the C/EBP- β transcription factor to an enhancer interacting with the IFNB1 promoter. This enhancer, that we have called FIRE for Far IFNB1 Regulatory Enhancer, is conserved in murine myeloid cells, where its looping to Ifnb1 is increased in a genetic model of Ifnb1 deregulation. Precisely, we show that in mu rine myeloid cells, the TRIM33 chromatin reader partially co-localizes with CTCF and cohesin on the chromatin, and knocking out Trim33 reinforces a loop between Ifnb1 and FIRE.
Source: GEO: Gene Expression Omnibus - Category: Genetics & Stem Cells Tags: Expression profiling by high throughput sequencing Mus musculus Source Type: research

Related Links:

Angew Chem Int Ed Engl. 2021 Sep 23. doi: 10.1002/anie.202110427. Online ahead of print.ABSTRACTNanozymes with intrinsic enzyme-like characteristics have attracted enormous research interest in biological application, due to their higher catalytic stability and activity than many natural enzymes. However, there is still a lack of facile approach for real-time evaluating the catalytic activity of nanozymes in living system, which limits their application in precise treatment of disease. Herein, we develop a novel manganese-semiconducting polymer-based nanozyme (MSPN) with oxidase-like activity for dynamically reporting the ...
Source: Angewandte Chemie - Category: Chemistry Authors: Source Type: research
Chem Commun (Camb). 2021 Sep 23. doi: 10.1039/d1cc04091j. Online ahead of print.ABSTRACTThe adenine N6-methylation m6A is a crucial modification that is associated with several biological functions. One of the two m6A demethylases FTO has arisen as an attractive target for the development of novel cancer therapies. Here, we describe a new design, synthesis and evaluation of a photo-responsive and selective inhibitor of FTO.PMID:34553720 | DOI:10.1039/d1cc04091j
Source: Chemical Communications - Category: Chemistry Authors: Source Type: research
g Yeng Looi Insight into cancer signaling pathways is vital in the development of new cancer treatments to improve treatment efficacy. A relatively new but essential developmental signaling pathway, namely Hedgehog (Hh), has recently emerged as a major mediator of cancer progression and chemoresistance. The evolutionary conserved Hh signaling pathway requires an in-depth understanding of the paradigm of Hh signaling transduction, which is fundamental to provide the necessary means for the design of novel tools for treating cancer related to aberrant Hh signaling. This review will focus substantially on the canonical Hh...
Source: Cancers - Category: Cancer & Oncology Authors: Tags: Review Source Type: research
Ovarian cancer is a common gynecologic aggressive neoplasm. The mortality of ovarian cancer is top among gynecologic malignancies due to the insidious onset, atypical early symptoms, and chemoresistance. Therefore, it is urgent to seek another promising treatment for ovarian cancer. Purified vitexin compound 1 (VB1) is a kind of neolignan from the seed of traditional Chinese herb vitex negundo that possessed diverse pharmacological effects. VB1 can exhibit anti-neoplastic activities against various cancers. However, the role of VB1 in ovarian cancer treatment has not been elaborated, and the mechanism is unknown. The aim o...
Source: Frontiers in Oncology - Category: Cancer & Oncology Source Type: research
Contributors : King L Hung ; Kathryn E Yost ; Liangqi Xie ; Quanming Shi ; Konstantin Helmsauer ; Jens Luebeck ; Robert Sch öpflin ; Joshua T Lange ; Rocio Chamorro ; Natasha E Weiser ; Celine Chen ; Maria E Valieva ; Ivy Tsz-Lo Wong ; Sihan Wu ; Siavash R Dehkordi ; Connor V Duffy ; Katerina Kraft ; Jun Tang ; Julia A Belk ; John C Rose ; M R Corces ; Jeffrey M Granja ; Utkrisht Rajkumar ; Jordan Friedlein ; An indya Bagchi ; Ansuman T Satpathy ; Robert Tijan ; Stefan Mundlos ; Vineet Bafna ; Anton G Henssen ; Paul S Mischel ; Zhe Liu ; Howard Y ChangSeries Type : Expression profiling by high throughput sequencingOrg...
Source: GEO: Gene Expression Omnibus - Category: Genetics & Stem Cells Tags: Expression profiling by high throughput sequencing Homo sapiens Source Type: research
Funding Opportunity PAR-21-329 from the NIH Guide for Grants and Contracts. The purpose of this Funding Opportunity Announcement (FOA) is to support collaborative research projects designed to address adverse sequelae of cancer therapies that persist and become chronic comorbidities or develop as delayed posttreatment effects. This FOA supports basic, translational, and clinical research projects that seek to identify the mechanisms of therapy-induced adverse sequelae, clinically characterize the adverse sequelae, or translate the mechanistic understanding into therapeutic approaches to prevent or minimize the development...
Source: NIH Funding Opportunities (Notices, PA, RFA) - Category: Research Source Type: funding
AbstractGlutamine metabolism is one of the hallmarks of cancers which is described as an essential role in serving as a major energy and building blocks supply to cell proliferation in cancer cells. Many malignant tumor cells always display glutamine addiction. The “kidney-type” glutaminase (GLS1) is a metabolism enzyme which plays a significant part in glutaminolysis. Interestingly, GLS1 is often overexpressed in highly proliferative cancer cells to fulfill enhanced glutamine demand. So far, GLS1 has been proved to be a significant target during the carci nogenesis process, and emerging evidence reveals that i...
Source: Clinical and Translational Oncology - Category: Cancer & Oncology Source Type: research
SAN DIEGO, Sept. 22, 2021 -- (Healthcare Sales &Marketing Network) -- Kintara Therapeutics, Inc. (Nasdaq: KTRA) ("Kintara" or the "Company"), a biopharmaceutical company developing novel cancer therapies for patients who are failing, ... Biopharmaceuticals, Oncology Kintara Therapeutics, glioblastoma multiforme
Source: HSMN NewsFeed - Category: Pharmaceuticals Source Type: news
Angew Chem Int Ed Engl. 2021 Sep 22. doi: 10.1002/anie.202111839. Online ahead of print.ABSTRACTTherapeutic peptides have been widely concerned because of their good biocompatibility, but their efficacy is limited by the inability to penetrate cell membranes, which is a key bottleneck in peptide drugs delivery. Herein, an in vivo self-assembly strategy is developed to induce phase separation of cell membrane that improves the peptide drugs internalization and anticancer efficacy. A phosphopeptide KYp is synthesized, containing an anticancer peptide [KLAKLAK] 2 (K) and a responsive moiety phosphorylated Y (Yp). After intera...
Source: Angewandte Chemie - Category: Chemistry Authors: Source Type: research
Cancer Res. 2021 Sep 21:canres.0736.2021. doi: 10.1158/0008-5472.CAN-21-0736. Online ahead of print.ABSTRACTMicroRNA-155 (miR-155) is overexpressed in various types of lymphomas and leukemias, suggesting that targeting miR-155 could be a potential platform for the development of precision medicine. Here we tested the anti-cancer activity of novel, chemically modified, triplex peptide nucleic acid (PNA)-based antimiRs compared to the current state-of-the-art conventional full length antimiRs. Next-generation modified PNAs that bound miR-155 by Watson-Crick and Hoogsteen domains possessed superior therapeutic efficacy in viv...
Source: Cell Research - Category: Cytology Authors: Source Type: research
More News: Cancer | Cancer & Oncology | Cancer Therapy | Genetics